Everyone is About to Become Lean and Muscled (new evidence) - Brad Stanfield

#1

chatGPT5.5 paid:

Tidy transcript

1. Understanding myostatin

In 2004, a baby was reported in Germany who, by any normal measure, seemed extraordinary. Within days of birth he had unusually visible muscles: his thighs and upper arms looked unusually well developed.

Doctors checked for disease but did not find an explanation. Genetic testing pointed to the cause: both copies of a gene affecting myostatin function were disrupted. Myostatin is a protein whose role is to restrain muscle growth. In simple terms, it acts as a brake on muscle formation. In this child, that brake was effectively absent.

The myostatin gene had only been identified a few years earlier, in 1997, and once scientists understood its role, the implications were obvious. If myostatin could be safely inhibited, it might be possible to treat conditions where muscle is progressively lost, such as muscular dystrophy, spinal muscular atrophy, or sarcopenia.

The problem was that, for nearly three decades, nobody had found a way to inhibit myostatin cleanly and safely enough for broad clinical use.

2. The problem created by modern weight-loss drugs

Modern weight-loss drugs have changed the landscape. Older drug treatments produced relatively modest weight loss. Semaglutide, sold as Ozempic or Wegovy depending on indication and market, raised that to roughly the mid-teens percentage range. Tirzepatide pushed weight loss into the 20% range. Retatrutide, a newer triple agonist, has recently produced about 28% body-weight loss in a large late-stage trial.

For someone starting at around 110 kg, that scale of loss can mean more than 30 kg lost, approaching the range previously associated with bariatric surgery.

But the catch is that some of the lost weight is not fat. Some is lean mass, including muscle. The video argues that the panic over “GLP-1 drugs melting muscle” needs context. Lean-mass loss is not unique to GLP-1 or incretin-based drugs. In many forms of weight loss, including dieting and bariatric surgery, a substantial minority of lost weight is lean tissue. The transcript states a rule of thumb of roughly one quarter of total weight loss being lean mass.

The practical aim is therefore not just weight loss, but high-quality weight loss: losing fat while preserving as much muscle and function as possible.

3. Why myostatin is attractive

The myostatin story began with dramatic mouse experiments. In 1997, researchers deleted the myostatin gene in mice, producing animals with very large muscles. The effect resembled “double-muscled” cattle.

That made myostatin an obvious target. If blocking it could increase or preserve muscle in humans, it might help with muscle-wasting diseases, ageing-related sarcopenia, and now the lean-mass loss associated with major pharmacological weight reduction.

The natural human myostatin-deficiency case seemed reassuring: a person could have very low myostatin activity and be unusually muscular without obvious severe developmental failure. But that did not mean that drugging the pathway would be easy.

4. Why earlier attempts struggled

The video explains that many early efforts used monoclonal antibodies against active myostatin. The problem is that active myostatin resembles other members of the TGF-beta / activin family. Blocking the wrong related proteins can create off-target effects.

So the field had a strong biological target, but poor selectivity. That is why many myostatin approaches generated enthusiasm but limited clinical success.

5. Apitegromab: the more selective approach

The newer drug discussed in the video is apitegromab. Its key distinction is that it does not mainly target active myostatin. Instead, it binds the pro- and latent forms of myostatin, before activation. This precursor form is more specific to myostatin, allowing more selective inhibition. Scholar Rock describes apitegromab as a fully human monoclonal antibody that inhibits myostatin activation by selectively binding pro- and latent myostatin in skeletal muscle.

Apitegromab has also been studied in spinal muscular atrophy. Published phase 2 evidence reported improved motor function in later-onset type 2 and 3 SMA, supporting further randomized testing.

6. Combining weight-loss drugs with muscle-preserving drugs

The video contrasts two strategies.

The first is apitegromab, the more selective myostatin inhibitor.

The second is bimagrumab, which blocks activin type II receptors more broadly. That is a more forceful intervention in the pathway. Bimagrumab has shown the ability to reduce fat mass while preserving or increasing lean mass, and a phase 2 study of bimagrumab with semaglutide reported preservation of lean mass with greater fat-mass reduction.

However, the broader mechanism may carry more concern about side effects. The video mentions muscle spasms, acne, LDL cholesterol increases, and programme pauses. Reuters reported in September 2025 that Lilly terminated one mid-stage bimagrumab/tirzepatide trial in people with type 2 diabetes for strategic reasons, while another non-diabetic obesity study continued; that report did not clearly say the trial was stopped because of safety signals.

7. The EMBRAZE trial

The main study discussed is EMBRAZE, a randomized, double-blind, placebo-controlled phase 2 trial of apitegromab added to tirzepatide in adults with overweight or obesity.

The design was simple: 102 adults received tirzepatide, and they were randomized to receive either apitegromab or placebo. After 24 weeks, the investigators measured total weight loss and body composition.

The trial found that apitegromab preserved lean mass compared with placebo. The published result was about 1.9 kg less lean-mass loss with apitegromab, representing about 54.9% retention of lean mass relative to placebo, despite similar overall weight loss.

The video’s key caution is important: preserving lean mass on a scan is not the same as proving better physical function. The transcript says the apitegromab group was not measurably stronger on grip strength or chair-stand tests. That distinction matters: body composition is a surrogate; strength, mobility, falls, frailty and quality of life are the clinically meaningful outcomes.

8. Practical advice given in the video

The video ends with the practical advice that, at present, the proven ways to reduce muscle loss during GLP-1 or tirzepatide-associated weight loss are still ordinary ones:

resistance training, adequate protein intake, and possibly creatine.

It also warns against grey-market SARMs and “muscle-preserving peptides”, such as YK11, arguing that they lack proper randomized human evidence and may carry risks including liver injury.

Summary

The video argues that modern obesity drugs are now powerful enough to create a new clinical problem: large weight loss can include meaningful lean-mass loss. It then presents myostatin inhibition as a possible solution.

The central claim is that apitegromab, a selective antibody that blocks activation of myostatin, may preserve lean mass during tirzepatide-induced weight loss. The EMBRAZE phase 2 trial supports that claim at the body-composition level: people receiving apitegromab plus tirzepatide lost a similar amount of total weight but lost less lean mass than those receiving tirzepatide plus placebo.

The video is strongest when it distinguishes between lean mass on a scan and functional benefit. It correctly warns that the trial does not yet prove better strength, mobility, or frailty outcomes.

Critique

The video is broadly plausible and based on a real, timely paper, but it has several weaknesses.

First, the transcript appears to contain an error: it says the German myostatin-deficient baby was born in 2024, but later correctly refers to the case as 2004. The famous human myostatin-deficiency report was from 2004, not 2024. That is probably a transcription or narration error, but it matters because the video frames the story historically.

Second, the video slightly overdramatises the “nearly 30 years nobody could switch off myostatin safely” point. It is fair that earlier approaches disappointed, but the history is not simply failure followed by one breakthrough. There have been multiple attempts across myostatin, activin receptors, follistatin-related approaches and ligand traps, with mixed efficacy, target-specific issues and endpoint problems.

Third, the bimagrumab section needs caution. The video says a programme was paused because of safety signals. The Reuters report I found says Lilly terminated one bimagrumab/tirzepatide trial in people with type 2 diabetes for “strategic business reasons”, while another study continued; that does not prove safety was the reason.

Fourth, lean mass is not identical to useful muscle. DXA lean mass includes water, organs and non-fat soft tissue, not just contractile muscle. If a drug preserves DXA lean mass but does not improve grip strength, chair-stand performance, walking speed or frailty outcomes, the clinical value remains uncertain.

Fifth, the EMBRAZE trial was small and short: 102 participants over 24 weeks. That is useful proof of concept, not proof of long-term safety or benefit. The key future questions are whether apitegromab preserves function over 1–2 years, whether it prevents sarcopenia in older adults, whether it improves outcomes after stopping tirzepatide, and whether long-term myostatin inhibition has tendon, cardiac, metabolic or malignancy-related signals.

Sixth, the practical advice is sensible. Resistance training and adequate protein are still the most evidence-grounded recommendations. Creatine is reasonable for many people, although in people with kidney disease or complex medication regimens it should be discussed with a clinician rather than treated as automatically harmless.

Bottom line

The video’s core message is sound: apitegromab plus tirzepatide appears to preserve more lean mass than tirzepatide alone, and this is a genuinely important development. The main caveat is that the study shows better body composition, not yet better strength, mobility, frailty or long-term health outcomes.

4 Likes
#2

Actual paper on th trial: Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial | Nature Medicine

1 Like
#3

This is an OK study. Main limitations:

  • They used DEXA to measure lean mass, so the increase in lean mass measured could be water weight.
  • No difference between the 2 groups in functional markers between those on the treatment, and those not on it. What good is added lean mass if it’s essentially dead weight?
  • The study didn’t take into account nutrition and physical activity.
  • There was no resistance training + tirzepatide arm, so we can’t observe how effective these myostain inhibitors are vs plain resistance training for muscle mass preservation, muscle function, muscle quality.

In light of recent MRI results on body composition post-weight loss on some GLP1s, it’s fair to ask questions about the real value of these myostatin inhibitors. Survodutide weight loss, for example, achieved lean loss ratio of -10%, meaning only 10% of weight loss came from lean mass. See here: Survodutide Once Weekly for the Treatment of Adults with Obesity (body composition results) . How much better can these myostatin inhibitors be, and will that justify their price?

1 Like
#4

Building Muscle While You Melt Fat: Can a Myostatin Antibody Rescue the “Skinny-Fat” Cost of GLP-1 Drugs?

Paper: Pratley et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial (EMBRAZE). Nature Medicine (2026). NCT06445075.

Adding the selective myostatin-blocking antibody apitegromab to the weight-loss drug tirzepatide cut lean-mass loss roughly in half over 24 weeks without changing how much total weight people lost. It is the first human evidence that selectively muting myostatin can protect muscle during incretin-driven weight loss — but the trial showed preserved scale mass, not preserved strength.

The GLP-1 era has a quiet problem. Drugs like tirzepatide and semaglutide strip weight off patients at an unprecedented rate, but a large slice of that loss is not fat. In this trial, among people on tirzepatide plus placebo, roughly 30% of every kilogram lost came from lean body mass — muscle, organ tissue and the water they carry. For an aging population already drifting toward sarcopenia, shedding muscle alongside fat is a poor trade.

Enter apitegromab, an antibody developed by Scholar Rock that grabs the precursor forms of myostatin before they can mature. Myostatin is the body’s brake on muscle growth; animals and rare humans lacking it are conspicuously muscular. Earlier myostatin drugs flopped, partly because they hit related proteins and caused off-target trouble. Apitegromab’s selling point is selectivity: it binds only myostatin’s latent forms and leaves the rest of the TGF-beta family alone. It already has a track record in spinal muscular atrophy, where it improved motor function.

EMBRAZE tested whether that selectivity could pay off in a far larger market: ordinary weight management. One hundred and two adults with overweight or obesity were randomized to tirzepatide plus apitegromab or tirzepatide plus placebo, dosed for 24 weeks. The headline result is clean. Both groups lost essentially the same total weight (about 11 to 12.5 kg), but the apitegromab group lost only 1.6 kg of lean mass versus 3.5 kg in the placebo group — a 1.9 kg difference, or a 54.9% relative retention of lean tissue. Because total weight loss was unchanged, the spared muscle was effectively “paid for” by extra fat loss: fat made up 85% of weight lost on apitegromab versus 70% on placebo.

Safety looked unremarkable: adverse events were comparable between arms and dominated by tirzepatide’s familiar gastrointestinal effects, with a hint of more fatigue and headache in the antibody group.

The catch sits in the fine print. This was a small, sponsor-run phase 2 study using a deliberately permissive statistical threshold, and — critically — the preserved muscle did not translate into measurably better grip strength or sit-to-stand performance. Whether apitegromab protects functional muscle or merely flatters a DEXA scan remains the open question.

Actionable Insights

The honest take-home is conceptual, because apitegromab is investigational and not yet available.

  1. The lean-mass tax is real and quantifiable. On tirzepatide alone, about 30% of total weight lost was lean mass; nearly a third of your “weight-loss win” can be muscle. Anyone using a GLP-1/GIP drug should treat muscle preservation as a primary objective, not an afterthought.
  2. Magnitude of the drug effect. Over 24 weeks, apitegromab spared an additional 1.9 kg of lean mass — preserving 54.9% of what would otherwise have been lost. Framed differently, it dropped the lean-mass share of total loss from 30.2% to 14.6%, roughly halving it. The standardized effect size, however, is modest (Cohen’s d approximately 0.4; see Part 2).
  3. Durability is partial. Eight weeks after stopping both drugs (week 32), the lean-mass advantage shrank from 1.9 kg to 0.9 kg and was only marginally significant. The benefit appears to require ongoing dosing. [Confidence: Medium]

Source:

  • Institution (lead): AdventHealth Translational Research Institute, Orlando, Florida (corresponding author R.E. Pratley). Sponsor and most co-authors: Scholar Rock, Inc., Cambridge, Massachusetts.
  • Sites: 7 clinical sites across the United States.
  • Country: United States.
  • Journal: Nature Medicine.
  • Impact Evaluation: The impact score of this journal is 49.2 (2024 two-year Journal Impact Factor; five-year JIF 52.4; CiteScore 91.9), evaluated against a typical high-end range of 0 to 60+ for top general and clinical medical journals, therefore this is an Elite impact journal.
#5

Timeline to Consumer Availability:

apitegromab is close to market, but only for spinal muscular atrophy (SMA) — not for the weight-loss/lean-mass-preservation use that the EMBRAZE paper you analyzed is about. Those are two very different timelines.

Track 1 — SMA (imminent). This is the lead indication and it’s essentially at the finish line. The FDA accepted the apitegromab Biologics License Application for children and adults with SMA, with a September 30, 2026 PDUFA action date. This followed a Complete Response Letter in September 2025 tied to observations at a third-party fill-finish facility (Catalent Indiana, part of Novo Nordisk) during a routine inspection — the CRL did not cite any efficacy or safety concerns about the drug itself. On the European side, the EMA decision is anticipated in mid-2026, with a European launch expected in the second half of 2026, starting with Germany. So for SMA patients, a U.S. launch could realistically come around Q4 2026 if approval lands on schedule. sec + 2

Track 2 — weight loss / lean-mass preservation (years away, speculative). This is the indication relevant to your longevity interest, and it is far earlier in development. EMBRAZE is a phase 2 proof-of-concept; there is no phase 3 program in obesity or cardiometabolic disease announced in the current disclosures. A drug at this stage typically needs at least one large pivotal phase 3 trial (likely 1–2+ years to run and read out), followed by BLA submission and review. A defensible rough estimate is 2029 or later, at the earliest, and only if phase 3 succeeds — a meaningful “if,” given the unresolved function question I flagged in the analysis. [Confidence: Low — this depends on trials not yet started.]

Other context worth knowing: Scholar Rock is also developing a subcutaneous version of apitegromab (the current form is IV infusion), which matters a lot for any future consumer/outpatient weight-management use. A phase 1 study of subcutaneous apitegromab showed favorable bioavailability with a pharmacodynamic profile comparable to IV administration. They also have a separate, earlier-stage anti-myostatin molecule (SRK-439) explicitly aimed at the muscle-preservation space. Scholar Rock, Inc.

So the honest bottom line: if you’re tracking this for the GLP-1/lean-mass use case specifically, it is not on a near-term consumer timeline — the 2026 approval news you’ll see in headlines is the rare-disease (SMA) indication, which won’t translate into off-the-shelf availability for weight management.

For the most current status, Scholar Rock’s investor relations page is the authoritative source, since these dates shift with regulatory and manufacturing developments.

But, many other myostatin inhibitors on their way:

1 Like
#6

Very exciting

#7

“— the preserved muscle did not translate into measurably better grip strength or sit-to-stand performance. Whether apitegromab protects functional muscle or merely flatters a DEXA scan remains the open question.”

From one of many 2004 articles about the myostatin deficient German boy (four years old at the time): “The boy doesn’t stand out among his peers on the playground, but when he puts his mind to it, he can perform feats of strength, said Dr. Markus Schuelke. ‘He’s a normal boy – you don’t see it, you wouldn’t recognize him out of a crowd,’ Schuelke said. ‘He can just lift heavy things.’ The boy can hold 7-pound weights with arms extended, something many adults cannot do.”

The boy had real strength. Maybe one of the other candidate drugs will be more on point.

2 Likes
#8

Yes - a really interesting story. Here is the full research paper that came out on the boy. It would be interesting to see ongoing status updates on him to see how the impact is on all the organs over time…

Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child

https://www.nejm.org/doi/full/10.1056/NEJMoa040933

#9

It would be interesting, but the free AI I like to use didn’t find anything. Maybe your AI can do better.

#10

All I could get from Claude 4.8:

The case you’re describing is the boy reported by Markus Schuelke’s group at Charité in Berlin in 2004 — the first confirmed human with a homozygous loss-of-function MSTN (myostatin) mutation. Here’s the important framing for an academic audience: only one primary research paper actually documents this child. It is accompanied by an editorial and a correspondence exchange in the same journal, and it rests on a small cluster of foundational cross-species papers. I’ve organized the literature into those tiers below. There is no published longitudinal follow-up paper on this specific patient — his identity was kept confidential, and the disease entry that exists in OMIM is based on this single case.

Tier 1 — Papers directly about the child

The primary case report
Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, Braun T, Tobin JF, Lee SJ. Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child. N Engl J Med. 2004;350(26):2682–2688.
DOI: 10.1056/NEJMoa040933 · PMID: 15215484 · https://www.nejm.org/doi/full/10.1056/NEJMoa040933

This is the paper. The child was born to a healthy mother who was a former professional sprinter from a family known for unusual strength. He showed protruding thigh and upper-arm muscles at birth, with hypertrophy confirmed by ultrasonography at six days of age and normal testosterone, IGF-1, and glucose. Schuelke et al. identified homozygosity for a splice donor site mutation in the MSTN gene; his mother was heterozygous for the same mutation. Specifically it is a g.IVS1+5G→A transition at the splice donor site of intron 1, causing a cryptic splice site 108 bp downstream and a severely truncated protein, not found in 200 control chromosomes. By age 4.5 he retained increased muscle bulk and was able to hold two 3-kg dumbbells in horizontal suspension with arms extended. The authors monitored cardiac function and, at the time of writing, had detected no signs of cardiomyopathy or conduction disturbance, while noting he was still too young to rule them out. Science News + 5

The accompanying editorial
McNally EM. Powerful Genes — Myostatin Regulation of Human Muscle Mass. N Engl J Med. 2004;350(26):2642–2644.
DOI: 10.1056/NEJMp048124 · https://www.nejm.org/doi/abs/10.1056/NEJMp048124

McNally situates the case within the TGF-β family and flags the dual-use implications, warning that myostatin blockade would likely move into athletics and physical enhancement. Science News

The correspondence exchange
Letters to the editor with author reply. N Engl J Med. 2004;351(10):1030–1031.

A short post-publication exchange (including a letter from Catipovic) debating interpretation and implications of the case, with a reply from the Schuelke group.

mcnally2004.pdf (111.8 KB)

#11

Other possible cases:

The confirmed human literature is strikingly thin. After two decades, the German boy is still the only verified case of complete (homozygous) myostatin loss in a person. Beyond him, there are essentially three additional peer-reviewed entries plus one widely-publicized case that never made it into the scientific literature. Here’s the honest universe of it.

A second clinical case — the Italian man (heterozygous, via chromosomal deletion)

Prontera P, Belcastro V, Calabresi P, Donti E. Myostatin depletion: a therapy for Ehlers-Danlos syndrome? Ann Neurol. 2010;67(1):147–148.
DOI: 10.1002/ana.21828 · PMID: 20186851 · https://onlinelibrary.wiley.com/doi/10.1002/ana.21828

available from: https://sci-hub.ru/10.1002/ana.21828

This is the most interesting and least-known human case. Prontera et al. reported a 42-year-old Italian man with a complex Ehlers-Danlos phenotype caused by a 13.7-Mb de novo heterozygous deletion of chromosome 2q23.3–q31.2, which removed the COL3A1, COL5A2, and myostatin (MSTN) genes. Because he lost one MSTN copy, haploinsufficiency produced “an exceptional constitutional muscular mass,” without muscle weakness, myalgia, or easy fatigability. The striking twist the authors proposed: they hypothesized that MSTN haploinsufficiency exerted a protective effect against the EDS clinical manifestations that the collagen-gene losses would otherwise have caused — hence the title’s question about myostatin depletion as an EDS therapy. It’s effectively a natural experiment in heterozygous human myostatin loss. OMIM + 2

The major recent development — a population-scale study (2026)

Humans with function-disrupting variants in the myostatin gene (MSTN) have increased skeletal muscle mass and strength, and less adiposity. Nat Commun. 2026;17:Article 3891.
DOI: 10.1038/s41467-026-70422-2 · Humans with function-disrupting variants in the myostatin gene (MSTN) have increased skeletal muscle mass and strength, and less adiposity | Nature Communications

This is the most important addition to the field in twenty years, and it shifts the question from single case reports to population genetics. It is a large multi-cohort genetic association analysis using data from 1.1 million individuals, examining function-disrupting MSTN mutations on body composition and cardiometabolic traits. Across whole-exome data from 11 cohorts, the authors found 13,454 individuals carrying rare nonsynonymous MSTN variants, of which 226 were predicted to partially or fully disrupt protein function (38 predicted loss-of-function, 188 predicted to impair function). Carriers showed decreased adiposity, increased lean mass, and increased grip strength and creatinine, and the team further characterized body composition using whole-body MRI from UK Biobank with deep-learning automated image segmentation for 77,572 individuals. In effect, this is the first well-powered look at what heterozygous myostatin deficiency looks like across a healthy adult population, with a graded (dose-dependent) phenotype. Nature + 3

The famous case that is NOT in the literature

You’ll encounter Liam Hoekstra (US, born 2005) in nearly every popular write-up. He appeared on TV as a toddler doing pull-ups and clinically resembled myostatin deficiency. But the published record is essentially absent: reports suggested his circulating myostatin was normal, with a working theory of a receptor-side defect, possibly the activin type IIB receptor (ACVR2B), and follow-ups have been thin. Treat this as a media case, not a peer-reviewed study — the ACVR2B explanation is speculation, never formally characterized in a journal. It’s worth flagging because the conceptual point is real: “myostatin deficiency” is really a small family of phenotypes — loss of the ligand, the receptor, or downstream signaling — that can look similar clinically. Myostatininhibitorshub

So the verified human picture is: one homozygous case (Schuelke 2004), one heterozygous deletion case (Prontera 2010), and now one large population study of function-disrupting carriers (2026), with Hoekstra sitting outside the literature.

#12

“The confirmed human literature is strikingly thin.” Probably because researchers have been looking at other things. Some exceptional athletes might be found to have a myostatin deficiency if there were enough interest in testing them. Under what circumstances would anyone be tested for it?

1 Like
#13

Agreed.

The animal research I was not so informed on; its very interesting and gives us a look at long term impacts.

Here’s the animal-model literature, which is indeed far larger and splits cleanly into two eras: the naturally occurring “double-muscling” mutations discovered in the late 1990s–2000s, and the deliberately engineered knockouts (ZFN → TALEN → CRISPR) from ~2014 onward. Organized by species.

Cattle

This is where myostatin biology started. Three groups independently nailed the double-muscling mutations in 1997, all in the same volume-year:

  • McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA. 1997;94(23):12457–12461. DOI: 10.1073/pnas.94.23.12457
  • Grobet L, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet. 1997;17(1):71–74. DOI: 10.1038/ng0997-71 — the Belgian Blue 11-bp deletion.
  • Kambadur R, et al. *Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle.*Genome Res. 1997;7(9):910–916. DOI: 10.1101/gr.7.9.910

Engineered cattle came later. Proudfoot et al. demonstrated that zygote injection of TALEN mRNA can produce gene-edited cattle and sheep, targeting MSTN in both species, and introduced an ovum-pickup/IVF/zygote-microinjection workflow for producing edited calves with specified genetics: nih

  • Proudfoot C, et al. Genome edited sheep and cattle. Transgenic Res. 2015;24(1):147–153. DOI: 10.1007/s11248-014-9832-x

More recently the field moved to DNA-free CRISPR ribonucleoprotein editing combined with somatic cell nuclear transfer to avoid exogenous DNA integration (e.g., a 2025 Reproductive Biology paper generating MSTN-KO calves via CRISPR/Cas9 RNP + SCNT).

Sheep

The sheep story is mechanistically the most interesting natural case, because the mutation isn’t a coding knockout — it’s a regulatory one:

  • Clop A, et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet. 2006;38(7):813–818. DOI: 10.1038/ng1810. The Texel GDF8 allele carries a G→A transition in the 3′ UTR that creates a target site for miR-1 and miR-206 — muscle-enriched microRNAs — causing translational inhibition of myostatin and contributing to the breed’s muscularity. Additional natural alleles were later described in Norwegian White Sheep (Boman et al. 2009, a coding frameshift) and others. Nature

Engineered sheep span the whole toolkit — TALEN editing of ovine fibroblasts (Han et al. 2014), the Proudfoot 2015 TALEN work above, CRISPR/Cas9 knockouts (Crispo et al. 2015), and recent dual-gene designs:

  • A MSTN^Del73C^ + FGF5-knockout sheep made by CRISPR/Cas9 produced a heritable double-muscle phenotype; both F0 and F1 mutants showed high-yield meat with smaller cross-sectional area and a higher number of muscle fibers per unit area, acting mechanistically through a MEK-ERK-FOSL1 axis (Biorxiv/PMC11452178). nih

Pigs

Pigs are the instructive exception: naturally occurring MSTN mutations had not produced significant muscle phenotypes in pigs, so essentially all the porcine work is engineered. The phenotype only emerged once the gene was deliberately disrupted: nih

  • Qian L, et al. Targeted mutations in myostatin by zinc-finger nucleases result in double-muscled phenotype in Meishan pigs. Sci Rep. 2015;5:14435. DOI: 10.1038/srep14435. Homozygous mutant pigs showed an apparent double-muscled phenotype with individual muscle mass increased by ~100% over wild-type at eight months via myofiber hyperplasia — and notably, 20% had one extra thoracic vertebra. nih
  • Wang K, et al. Efficient generation of myostatin mutations in pigs using the CRISPR/Cas9 system. Sci Rep. 2015;5:16623. DOI: 10.1038/srep16623
  • Rao S, et al. Efficient modification of the myostatin gene in porcine somatic cells and generation of knockout piglets. Mol Reprod Dev. 2016;83(1):61–70. DOI: 10.1002/mrd.22591 (TALEN)
  • Wang K, et al. CRISPR/Cas9-mediated knockout of myostatin in Chinese indigenous Erhualian pigs. Transgenic Res. 2017;26(6):799–805.

A relevant phenotyping follow-up is the Meishan Mstn^−/−^ metabolic study showing decreased subcutaneous and leaf fat, increased insulin sensitivity, and browning of subcutaneous adipose tissue compared with wild-type pigs (PMC5471021) — a useful bridge to the human metabolic interest in myostatin blockade. nih

Dogs

Both a natural and an engineered case exist, and they’re often discussed together:

  • Mosher DS, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 2007;3(5):e79. DOI: 10.1371/journal.pgen.0030079. The “bully whippet”: double-muscled individuals carry two copies of a two-base-pair deletion in exon 3 leading to a premature stop at amino acid 313, while heterozygotes are on average more muscular and significantly faster in competitive racing — the first quantitative link between an MSTN mutation and athletic performance, and a clean illustration of the gene-dose effect. nih
  • Zou Q, et al. Generation of gene-target dogs using CRISPR/Cas9 system. J Mol Cell Biol. 2015;7(6):580–583. The beagles “Hercules” and “Tiangou” — the first dogs modified by CRISPR/Cas9, in which knocking out myostatin produced a pair with roughly twice the muscle mass of normal beagles, with the stated aim of building canine disease models. Science
#14

In the animal research, what is the impact on lifespan and healthspan of the animals with myostatin inhibition?

The animal data here is genuinely more interesting — and more cautionary — than the popular “extra muscle = healthier” narrative implies. The short version: the single most-cited lifespan study found that partial myostatin loss extended life but complete knockout did not, and the muscle that complete knockouts build is metabolically and mechanically lower-quality. Here’s the breakdown.

Lifespan: dose-dependent, and the full knockout doesn’t win

The one direct longevity experiment is Mendias et al. (Aging Cell, 2015), and its result is counterintuitive. MSTN^+/−^ and MSTN^−/−^ mice were both protected from aging-related declines in muscle mass and contractility, but only the heterozygous MSTN^+/−^ mice showed roughly a 15% increase in maximal lifespan, with no lifespan difference detected between wild-type and full-knockout MSTN^−/−^ mice. The statistics make the dissociation stark: wild-type vs. full knockout gave P = 0.85 (no difference), while wild-type vs. heterozygote gave P = 0.003. nihPubMed

Mendias CL, et al. Haploinsufficiency of myostatin protects against aging-related declines in muscle function and enhances the longevity of mice. Aging Cell. 2015;14(4):704–706. PMID: 25808276. Haploinsufficiency of myostatin protects against aging-related declines in muscle function and enhances the longevity of mice - PMC

Two important caveats for interpreting that 15%. First, it’s a single study with modest cohorts. Second, the likely mechanism is partly confounded by lab-mouse metabolism: knockouts and heterozygotes stay lean and resist age-related fat expansion, so the lifespan gap may reflect wild-type controls drifting into metabolic morbidity as much as a direct anti-aging effect — the “big mice die young, but lean mice avoid metabolic disease” tension. So I’d hold the lifespan claim at moderate confidence, and specifically the claim that complete loss extends life at low confidence (the data point the other way).

Healthspan benefits

  • Sarcopenia protection. Both partial and complete loss preserve muscle mass and contractile function into oldest-old age (the durable, well-replicated finding).
  • Metabolic. Reduced adiposity, smaller adipocytes, resistance to age-related and diet-induced fat gain, and improved insulin sensitivity. Postnatal pharmacological inhibition reproduces this: an anti-myostatin antibody given to old mice increased muscle mass and strength and improved insulin sensitivity (PNAS, 2016), which matters because it shows benefits don’t require lifelong/developmental loss. PNAS
  • Cardiac (in aging). 27- to 30-month-old myostatin-knockout mice showed less myocardial fibrosis, less ventricular dilation, and improved cardiac function compared with wild-type — consistent with myostatin acting as a pro-fibrotic signal in the aged heart. American Physiological Society
  • Bone. Myostatin-deficient mice tend to have higher cortical thickness and bone mineral density with fewer osteoclasts — a net positive on the skeletal side.

Healthspan costs (the part usually omitted)

This is where the “double-muscled” phenotype shows its price, and it clusters into three linked problems:

1. Lower muscle quality (force per unit area). The muscle is bigger and stronger in absolute terms but weaker per cross-section. Lack of myostatin compromises force production in association with loss of oxidative characteristics — increased type IIB fibers with tubular aggregates, and decreased mitochondrial DNA-to-nuclear DNA ratio and mitochondrial number, indicating mitochondrial depletion (Amthor et al., PNAS 2007). PNAS

2. Poor endurance and a metabolic shift toward glycolysis. Muscles from Mstn^−/−^ mice, although larger and stronger, fatigue extremely rapidly; myostatin deficiency shifts muscle from aerobic toward anaerobic metabolism — decreased mitochondrial respiration, reduced PPAR transcriptional regulators, increased enolase activity, and exercise-induced lactic acidosis — which diminishes exercise capacity. Critically, the same study showed myostatin blockade via AAV propeptide in adult wild-type mice also diminished exercise capacity, so this isn’t purely a developmental artifact of the knockout (Mouisel et al., Am J Physiol Regul Integr Comp Physiol, 2014). American Physiological SocietyAmerican Physiological Society

3. Weak, brittle tendons. The connective tissue doesn’t keep pace with the muscle. Tendons of myostatin-null mice were smaller, stiffer, hypocellular, with decreased fibroblast density and reduced type I collagen, scleraxis, and tenomodulin — and this increased stiffness underlies greater force deficits after contraction-induced injury (Mendias et al., PNAS 2008). So you get oversized muscle pulling on under-built tendon, raising injury susceptibility. PNAS

A cardiac caveat cuts against the rosy aging picture too: while germline knockout doesn’t cause hypertrophy at baseline, selective deletion of myostatin in cardiomyocytes of adult mice increased lethality and led to heart failure and ventricular hypertrophy — meaning context (which tissue, what timing) determines whether myostatin loss helps or harms the heart. MDPI

The synthesis for a longevity framing

Two design variables decide whether myostatin inhibition reads as pro- or anti-healthspan in these models: degree and timing. Complete, lifelong (developmental) loss maximizes muscle bulk but buys the quality, endurance, and tendon penalties without a lifespan gain. Partial reduction — and postnatal/adult pharmacological inhibition — captures the sarcopenia-protection and metabolic benefits with the lifespan signal and milder structural costs. That maps neatly onto why the therapeutic field pursues titratable antibody/ligand-trap blockade in adults rather than trying to mimic the full knockout.

One more point that’s directly relevant to the healthspan tradeoff: the deficits aren’t fixed. Myostatin-deficient muscle is not “genetically locked” — endurance exercise reduces fiber size, increases oxidative properties and capillary density, and improves force generation in Mstn^−/−^ mice, partially reversing the mitochondrial/fatigue penalty. So the oxidative cost of myostatin loss is, at least in part, trainable away. ScienceDirect

#15

On the broader issue messing around with myostatin is not fixing the reason why satellite cells don’t differentiate and muscles get weaker as people get older. I don’t personally think this is a sensible target for intervention - unless you have no others - but there are better ones eg acetylation.